Citigroup
CRSP icon

Citigroup’s CRISPR Therapeutics CRSP Stock Holding History

Citigroup’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.23M Buy
114,316
+92,346
+420% +$4.87M ﹤0.01% 1961
2026
Q1 		$1.05M Sell
21,970
-110,723
-83% -$5.84M ﹤0.01% 3086
2025
Q4 		$6.96M Buy
132,693
+72,204
+119% +$4.32M ﹤0.01% 1787
2025
Q3 		$3.92M Sell
60,489
-66,403
-52% -$3.81M ﹤0.01% 2149
2025
Q2 		$6.17M Sell
126,892
-78,756
-38% -$3.05M ﹤0.01% 1728
2025
Q1 		$7M Buy
205,648
+95,292
+86% +$4.04M ﹤0.01% 1629
2024
Q4 		$4.34M Buy
110,356
+85,934
+352% +$4.06M ﹤0.01% 2111
2024
Q3 		$1.15M Sell
24,422
-13,682
-36% -$694K ﹤0.01% 3156
2024
Q2 		$2.06M Sell
38,104
-63,365
-62% -$3.67M ﹤0.01% 2331
2024
Q1 		$6.92M Sell
101,469
-9,616
-9% -$688K ﹤0.01% 1498
2023
Q4 		$6.95M Sell
111,085
-1,026
-0.9% -$56.7K ﹤0.01% 1396
2023
Q3 		$5.09M Buy
112,111
+3,617
+3% +$187K ﹤0.01% 1421
2023
Q2 		$6.09M Sell
108,494
-82,521
-43% -$4.68M ﹤0.01% 1378
2023
Q1 		$8.64M Buy
191,015
+66,067
+53% +$3.21M 0.01% 1226
2022
Q4 		$5.08M Buy
124,948
+8,354
+7% +$443K ﹤0.01% 1469
2022
Q3 		$7.62M Buy
116,594
+25,340
+28% +$1.84M 0.01% 1292
2022
Q2 		$5.55M Buy
91,254
+60,876
+200% +$3.58M ﹤0.01% 1480
2022
Q1 		$1.91M Sell
30,378
-410
-1% -$25.7K ﹤0.01% 2391
2021
Q4 		$2.33M Buy
30,788
+2,275
+8% +$199K ﹤0.01% 2489
2021
Q3 		$3.19M Sell
28,513
-4,648
-14% -$584K ﹤0.01% 2134
2021
Q2 		$5.37M Buy
33,161
+7,135
+27% +$868K ﹤0.01% 1838
2021
Q1 		$3.17M Buy
26,026
+4,765
+22% +$719K ﹤0.01% 2156
2020
Q4 		$3.26M Sell
21,261
-14,151
-40% -$1.67M ﹤0.01% 2408
2020
Q3 		$2.96M Sell
35,412
-9,802
-22% -$869K ﹤0.01% 2304
2020
Q2 		$3.32M Sell
45,214
-14,489
-24% -$847K ﹤0.01% 2251
2020
Q1 		$2.53M Buy
59,703
+34,625
+138% +$1.79M ﹤0.01% 2261
2019
Q4 		$1.53M Buy
25,078
+15,935
+174% +$870K ﹤0.01% 3292
2019
Q3 		$375K Sell
9,143
-5,347
-37% -$256K ﹤0.01% 4610
2019
Q2 		$683K Sell
14,490
-2,466
-15% -$98.6K ﹤0.01% 4099
2019
Q1 		$605K Sell
16,956
-42
-0.2% -$1.45K ﹤0.01% 3976
2018
Q4 		$486K Buy
16,998
+5,603
+49% +$195K ﹤0.01% 4151
2018
Q3 		$505K Buy
11,395
+1,278
+13% +$66.9K ﹤0.01% 4264
2018
Q2 		$595K Buy
10,117
+8,795
+665% +$501K ﹤0.01% 3905
2018
Q1 		$61K Buy
1,322
+17
+1% +$702 ﹤0.01% 6007
2017
Q4 		$30K Buy
1,305
+1,295
+12,950% +$24.6K ﹤0.01% 6497
2017
Q3 		$0 Buy
+10
New +$181 ﹤0.01% 7271
2017
Q2 		– Sell
-100
Closed -$2K – 7352
2017
Q1 		$2K Buy
+100
New +$1.96K ﹤0.01% 6987

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's CRSP Position: Q2 2026 in Review

Citigroup increased its CRISPR Therapeutics (CRSP) stake by 420% in Q2 2026, buying an estimated $4.87M and bringing the position to 114,316 shares worth $6.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Citigroup first reported a position in CRSP in Q1 2017 and has held it in 37 quarters since. The position peaked at $8.64M in Q1 2023. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Citigroup held 114,316 shares of CRISPR Therapeutics worth $6.23M as of Q2 2026.
  • Citigroup bought 92,346 CRISPR Therapeutics shares in Q2 2026, an estimated $4.87M.
  • CRISPR Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1961 holding.
  • Citigroup first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Citigroup's CRISPR Therapeutics position peaked at $8.64M in Q1 2023.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.